A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
Condition: HER2-PositiveRecurrent or Metastatic Breast Cancer Interventions: Drug: SHR-A1811 Injection; Drug: SHR-A1811 Injection ； Pertuzumab Injection; Drug: Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection Sponsor: Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
Conditions: HER2-PositiveRecurrent or Metastatic Breast Cancer Interventions: Drug: SHR-A1811 Injection; Drug: SHR-A1811 Injection ； Pertuzumab Injection; Drug: Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection Sponsors: Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases
Conditions: Breast Cancer; Metastatic Breast Cancer Intervention: Drug: Trastuzumab-Deruxtecan (T-DXd) Sponsors: MedSIR; Daiichi Sankyo, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of the Proposed Biosimilar PERT-IJS Versus EU-Perjeta ® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Condition: HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Interventions: Biological: PERT-IJS plus trastuzumab, carboplatin and docetaxel; Biological: Perjeta plus trastuzumab, carboplatin and docetaxel Sponsor: Biocon Biologics UK Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
